Legacy Capital Partners’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
$5.85M Buy
80,143
+750
+0.9% +$50.4K 1.93% 12
2021
Q4
$4.95M Sell
79,393
-1,765
-2% -$104K 1.6% 19
2021
Q3
$4.8M Sell
81,158
-1,113
-1% -$73.3K 1.74% 17
2021
Q2
$5.5M Buy
82,271
+3,695
+5% +$241K 1.97% 12
2021
Q1
$4.96M Buy
78,576
+23,756
+43% +$1.48M 1.87% 14
2020
Q4
$3.4M Sell
54,820
-5,495
-9% -$338K 1.33% 21
2020
Q3
$3.64M Buy
60,315
+3,050
+5% +$184K 1.47% 19
2020
Q2
$3.37M Buy
57,265
+556
+1% +$33.3K 1.45% 20
2020
Q1
$3.16M Sell
56,709
-2,635
-4% -$161K 1.57% 18
2019
Q4
$3.81M Buy
59,344
+15,582
+36% +$892K 1.54% 19
2019
Q3
$2.22M Buy
43,762
+15,685
+56% +$737K 0.97% 39
2019
Q2
$1.27M Buy
28,077
+20,045
+250% +$934K 0.57% 57
2019
Q1
$383K Hold
8,032
0.18% 97
2018
Q4
$418K Hold
8,032
0.22% 91
2018
Q3
$499K Sell
8,032
-100
-1% -$5.93K 0.23% 85
2018
Q2
$450K Sell
8,132
-2,600
-24% -$140K 0.22% 87
2018
Q1
$679K Sell
10,732
-11
-0.1% -$708 0.34% 73
2017
Q4
$658K Sell
10,743
-1
-0% -$63 0.33% 66
2017
Q3
$685K Buy
10,744
+662
+7% +$38.7K 0.36% 67
2017
Q2
$562K Buy
10,082
+339
+3% +$18.4K 0.3% 73
2017
Q1
$530K Buy
9,743
+1,611
+20% +$88.4K 0.3% 72
2016
Q4
$476K Buy
8,132
+1,650
+25% +$90.2K 0.29% 76
2016
Q3
$350K Sell
6,482
-2,000
-24% -$128K 0.22% 92
2016
Q2
$624K Sell
8,482
-368
-4% -$26K 0.39% 67
2016
Q1
$566K Sell
8,850
-400
-4% -$25.2K 0.36% 70
2015
Q4
$637K Hold
9,250
0.41% 66
2015
Q3
$548K Sell
9,250
-1,000
-10% -$63.4K 0.37% 73
2015
Q2
$683K Sell
10,250
-100
-1% -$6.59K 0.44% 69
2015
Q1
$668K Sell
10,350
-200
-2% -$12.5K 0.43% 68
2014
Q4
$623K Hold
10,550
0.4% 70
2014
Q3
$540K Hold
10,550
0.36% 70
2014
Q2
$512K Hold
10,550
0.33% 73
2014
Q1
$549K Sell
10,550
-200
-2% -$10.6K 0.39% 70
2013
Q4
$572K Hold
10,750
0.41% 66
2013
Q3
$498K Sell
10,750
-25
-0.2% -$1.1K 0.37% 70
2013
Q2
$482K Buy
+10,775
New +$468K 0.37% 68

Other funds holding BMY

Legacy Capital Partners's BMY Position: Q1 2022 in Review

Legacy Capital Partners increased its Bristol-Myers Squibb (BMY) stake by 0.94% in Q1 2022, buying an estimated $50.4K and bringing the position to 80,143 shares worth $5.85M. The position accounts for 1.93% of the portfolio, ranked #12.

Legacy Capital Partners first reported a position in BMY in Q2 2013 and has held it in 36 quarters since. 2,515 funds tracked by Wall St. Rank hold BMY as of Q1 2022.

  • Legacy Capital Partners held 80,143 shares of Bristol-Myers Squibb worth $5.85M as of Q1 2022.
  • Legacy Capital Partners bought 750 Bristol-Myers Squibb shares in Q1 2022, an estimated $50.4K.
  • Bristol-Myers Squibb made up 1.93% of Legacy Capital Partners's portfolio in Q1 2022, its #12 holding.
  • Legacy Capital Partners first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 36 quarters since.
  • 2,515 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2022.

Based on Legacy Capital Partners's 13F filing for Q1 2022, filed 11 Apr 2022.